Damora Therapeutics, Inc. (DMRA) vs Kardigan, Inc. (KARD)

A side-by-side comparison of Damora Therapeutics, Inc. and Kardigan, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Damora Therapeutics, Inc. logo
DMRA
Damora Therapeutics, Inc.
$1.16B
$18.91HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Kardigan, Inc. logo
KARD
Kardigan, Inc.
$1.25B
$14.05HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT

Total return — DMRA vs KARD

growth of $100 · dividends reinvested · last 1y
DMRA -4.8% (-4.8%/yr)KARD -30.7% (-30.7%/yr)DMRA compounded faster over this window
6080100120140160Start $100$95$69
DMRA KARD

DMRA vs KARD: by the numbers

  • •KARD is the larger company ($1.25B vs $1.16B market cap).

Metrics side by side

Valuation

MetricDMRAKARD
P/B ratio3.012.04

Profitability

MetricDMRAKARD
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-50.93%N/A
ROIC-52.44%-57.11%

Growth (annualized)

MetricDMRAKARD
Total return CAGR (5Y)-25.05%N/A

Go deeper

Full DMRA analysisFull KARD analysisInteractive comparison tool

Dig into the metrics

Damora Therapeutics ROEKardigan ROEDamora Therapeutics operating marginKardigan operating marginDamora Therapeutics revenue growthKardigan revenue growthDamora Therapeutics free cash flowKardigan free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.